Literature DB >> 20806183

Chromogranin A (CgA)--the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood.

Piotr Glinicki1, Wojciech Jeske.   

Abstract

Chromogranin A (CgA) is regarded as a major, nonspecific neuroendocrine tumour (NET) marker. The results of CgA blood concentration, however, may actually be influenced by various factors or coexisting pathological conditions. Among the factors causing a substantial increase of the blood CgA concentration are: treatment with proton-pump inhibitors or H₂-receptor blockers, chronic atrophic gastritis (type A), impaired renal function, prostate cancer and BPH, and rheumatoid arthritis with high level of RF IgM. In addition, the sort of investigated biological material (whether it is serum or plasma) is of importance. There are also many conditions which may have a moderate or little influence on the concentration of CgA, among them are: inflammatory bowel disease (ulcerative colitis and Crohn's disease), deteriorating liver function, untreated essential hypertension, heart failure, hypercortisolism, pregnancy, and, in some subjects, ingestion of a meal. Proper assessment of the CgA results requires detailed knowledge about various factors, drugs, and pathological conditions influencing its concentration in blood.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20806183

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  8 in total

1.  Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

Authors:  Somer Matar; Anna Malczewska; Kjell Oberg; Lisa Bodei; Harry Aslanian; Anna Lewczuk-Myślicka; Pier Luigi Filosso; Alejandro L Suarez; Agnieszka Kolasińska-Ćwikła; Matteo Roffinella; Beata Kos-Kudła; Jarosław B Ćwikła; Ignat A Drozdov; Mark Kidd; Irvin M Modlin
Journal:  Neuroendocrinology       Date:  2019-04-16       Impact factor: 4.914

Review 2.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

3.  Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience.

Authors:  A Filice; A Fraternali; A Frasoldati; M Asti; E Grassi; L Massi; M Sollini; A Froio; P A Erba; A Versari
Journal:  J Oncol       Date:  2012-08-09       Impact factor: 4.375

Review 4.  Chromogranin A as a valid marker in oncology: Clinical application or false hopes?

Authors:  Stavros Gkolfinopoulos; Konstantinos Tsapakidis; Konstantinos Papadimitriou; Demetris Papamichael; Panteleimon Kountourakis
Journal:  World J Methodol       Date:  2017-03-26

5.  Neutrophil count as the centerpiece in the joined association networks of inflammatory and cell damage markers, and neuroendocrine stress markers in patients with stable angina pectoris following stenting.

Authors:  Tamás Horváth; Gyöngyi Serfőző; Ádám Györkei; Imre Földesi; Tamás Forster; Margit Keresztes
Journal:  PLoS One       Date:  2019-04-11       Impact factor: 3.240

6.  Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms-A Preliminary Study.

Authors:  Barbara Bober; Marek Saracyn; Kornelia Zaręba; Arkadiusz Lubas; Paweł Mazurkiewicz; Ewelina Wilińska; Grzegorz Kamiński
Journal:  J Clin Med       Date:  2022-02-10       Impact factor: 4.241

7.  Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis.

Authors:  Zoltan Herold; Magdolna Herold; Peter Nagy; Attila Patocs; Marton Doleschall; Aniko Somogyi
Journal:  J Diabetes Investig       Date:  2020-02-03       Impact factor: 4.232

8.  Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.

Authors:  Gustav Mikkelsen; Arne Åsberg; Maria E Hultström; Knut Aasarød; Gunhild G Hov
Journal:  Int J Biol Markers       Date:  2017-10-31       Impact factor: 2.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.